Description
HAMNO is a novel protein interaction inhibitor of replication protein A (RPA), which is involved in the ATR/Chk1 pathway. HAMNO acts by binding to the N-terminal DBD-F domain of RPA70. HAMNO inhibits both ATR autophosphorylation and phosphorylation of RPA32 Ser33 by ATR. It is a potential treatment of cancer